{
    "clinical_study": {
        "@rank": "121069", 
        "arm_group": {
            "arm_group_label": "DTG/CBZ", 
            "arm_group_type": "Experimental", 
            "description": "All subjects will be assigned to a single-sequence of three treatment periods without washout. Subjects will receive DTG 50 mg once daily (OD) for 5 days (Period 1), followed by CBZ 100 mg twice daily (BID) for 3 days (days 1-3 of Period 2), CBZ 200 mg BID for 3 days (days 4-6 of Period 2), CBZ 300mg BID for 10 days (days 7-16 of Period 2), followed by DTG 50 mg OD in combination with CBZ 300mg BID for 5 days (Period 3)."
        }, 
        "brief_summary": {
            "textblock": "This study will be a phase I, open label, three period, fixed sequence crossover study to\n      evaluate the effect of Carbamazepine (CBZ) on the steady-state pharmacokinetics of\n      Dolutegravir (DTG) and on the safety and tolerability of DTG. Subjects will have a screening\n      visit within 30 days prior to the first dose of study drug, three treatment periods, and a\n      follow-up visit 7-14 days after the last dose of study drug. There is no washout between\n      treatment periods."
        }, 
        "brief_title": "Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult Subjects", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Infection, Human Immunodeficiency Virus", 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "Immunologic Deficiency Syndromes"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy as determined by a responsible and experienced physician, based on a medical\n             evaluation including [medical history, physical examination, laboratory tests and\n             cardiac monitoring]. A subject with a clinical abnormality or laboratory parameter(s)\n             which is/are not specifically listed in the inclusion or exclusion criteria, outside\n             the reference range for the population being studied may be included only if the\n             Investigator agrees and documents that the finding is unlikely to introduce\n             additional risk factors and will not interfere with the study procedures.\n\n          -  Male/females aged between 18 and 65 years of age inclusive, at the time of signing\n             the informed consent.\n\n          -  A female subject is eligible to participate if she is of: non-childbearing potential\n             defined as pre-menopausal females with a documented tubal ligation, bilateral\n             oophorectomy or hysterectomy [for this definition, \"documented\" refers to the outcome\n             of the investigator's/designee's review of the subject's medical history for study\n             eligibility, as obtained via a verbal interview with the subject or from the\n             subject's medical records]; or postmenopausal defined as 12 months of spontaneous\n             amenorrhea [in questionable cases a blood sample with simultaneous follicle\n             stimulating hormone (FSH) >40 milli international units per milliliter (MIU/mL) and\n             estradiol <40 picograms (pg)/mL (<147 picomole per liter (pmol/L) is confirmatory];\n             Child-bearing potential with negative pregnancy test as determined by [serum or\n             urine] human chorionic gonadotropin (hCG) test at screening or prior to dosing AND\n             Agrees to use one of the contraception methods for an appropriate period of time (as\n             determined by the product label or investigator) prior to the start of dosing to\n             sufficiently minimize the risk of pregnancy at that point. Female subjects must agree\n             to use contraception until 5 days post-last dose. OR has only same-sex partners, when\n             this is her preferred and usual lifestyle.\n\n          -  Body weight >=50 kilograms (Kg) for males and >=45 Kg for females and body mass index\n             (BMI) within the range 18.5 - 31.0 Kg/m^2 (square meters) (inclusive).\n\n          -  Alanine aminotransferase, alkaline phosphatase and bilirubin <= 1.5x Upper Limit of\n             Normal (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated\n             and direct bilirubin <35%). A single repeat is allowed for eligibility determination.\n\n          -  Based on single corrected QT interval (QTc) value: QT duration corrected for heart\n             rate by Bazett's formula (QTcB) <450 millisecond (msec); or QTc <480 msec in subjects\n             with Bundle Branch Block.\n\n          -  A negative HLA-B*1502 allele screening assessment for subjects of Asian ethnicity\n             only.\n\n          -  Capable of giving written informed consent, which includes compliance with the\n             requirements and restrictions listed in the consent form\n\n        Exclusion Criteria:\n\n          -  A positive pre-study drug/alcohol screen.\n\n          -  A positive test for human immunodeficiency virus (HIV) antibody.\n\n          -  Pregnant females as determined by positive [serum or urine] hCG test at screening or\n             prior to dosing.\n\n          -  History of regular alcohol consumption within 6 months of the study defined as: an\n             average weekly intake of >14 drinks for males or >7 drinks for females. One drink is\n             equivalent to 12 g of alcohol: 12 ounces (360 mL) of beer, 5 ounces (150 mL) of wine\n             or 1.5 ounces (45 mL) of 80 proof distilled spirits.\n\n          -  History of sensitivity to any of the study medications, or components thereof or a\n             history of drug or other allergy that, in the opinion of the investigator or\n             GlaxoSmithKline (GSK) Medical Monitor, contraindicates their participation. Subjects\n             will allergy to tricyclic antidepressants should not be enrolled.\n\n          -  Where participation in the study would result in donation of blood or blood products\n             in excess of 500 mL within a 56 day period.\n\n          -  The subject has participated in a clinical trial and has received an investigational\n             product within the following time period prior to the first dosing day in the current\n             study: 30 days, 5 half-lives or twice the duration of the biological effect of the\n             investigational product (whichever is longer).\n\n          -  Lactating females.\n\n          -  The subject's systolic blood pressure is outside the range of 90-140 millimeters of\n             mercury (mmHg), or diastolic pressure is outside the range of 45-90 mmHg, or heart\n             rate is outside the range of 50-100 beats per minute (bpm) for female subjects or\n             45-100 bpm for male subjects. A single repeat is allowed for eligibility\n             determination.\n\n          -  Exclusion criteria for screening ECG (a single repeat is allowed for eligibility\n             determination): Heart rate for males <45 and >110 bpm and females <50 and >100 bpm;\n             PR interval <120 and >220 msec, QRS duration <70 and >120 msec, QTc interval (Bazett)\n             >450 msec. Evidence of previous myocardial infarction (Does not include ST segment\n             changes associated with repolarization); any clinically significant arrhythmia which,\n             in the opinion of the investigator and GSK Medical Monitor, will interfere with the\n             safety for the individual subject; any conduction abnormality (including but not\n             specific to left or right incomplete bundle branch block, atrioventricular block [2nd\n             degree or higher], Wolf Parkinson White [WPW] syndrome), sinus pauses>3 seconds, and\n             non-sustained or sustained ventricular tachycardia (>=3 consecutive ventricular\n             ectopic beats).\n\n          -  Platelets, white blood cell count or hemoglobin below the lower limit of normal.  A\n             single repeat is allowed for eligibility determination.\n\n          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody\n             result within 3 months of screening\n\n          -  Current or chronic history of liver disease, or known hepatic or biliary\n             abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).\n\n          -  History of suicide ideation or severe depression.\n\n          -  History of hepatic porphyria (e.g., acute intermittent porphyria, variegate\n             porphyria, porphyria cutanea tarda.\n\n          -  History of previous bone marrow depression (e.g., prior viral or drug related bone\n             marrow depression)\n\n          -  Unable to refrain from the use of prescription or non-prescription drugs, including\n             vitamins, herbal and dietary supplements (including St. John's Wort) within 7 days\n             (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is\n             longer) prior to the first dose of study medication, unless in the opinion of the\n             investigator and GSK Medical Monitor the medication will not interfere with the study\n             procedures or compromise subject safety.\n\n          -  Unwillingness or inability to follow the procedures outlines in the protocol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01967771", 
            "org_study_id": "200901"
        }, 
        "intervention": [
            {
                "arm_group_label": "DTG/CBZ", 
                "description": "DTG will be supplied as 50 mg tablet to be administered orally", 
                "intervention_name": "DTG", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "DTG/CBZ", 
                "description": "CBZ will be supplied as 100 mg and 200 mg extended release tablet to be administered orally", 
                "intervention_name": "CBZ", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Carbamazepine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "healthy volunteers", 
            "drug interaction", 
            "carbamazepine", 
            "Dolutegravir", 
            "pharmacokinetics"
        ], 
        "lastchanged_date": "January 23, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Overland Park", 
                    "country": "United States", 
                    "state": "Kansas", 
                    "zip": "66211"
                }, 
                "name": "GSK Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I, Open Label, Randomized, Three Period, Fixed Sequence Crossover Study to Evaluate the Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (200901)", 
        "overall_official": {
            "affiliation": "ViiV Healthcare", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "PK parameters will include: Steady state plasma DTG concentration at the end of the dosing interval (Ctau), maximum concentration (Cmax), area under the time-concentration curve over the dosing interval [AUC(0-tau)], apparent clearance following oral dosing (CL/F), terminal phase half life (t1/2), concentration at time zero (C0) and minimum concentration (Cmin)", 
            "measure": "Steady state plasma DTG pharmacokinetics (PK) parameters", 
            "safety_issue": "No", 
            "time_frame": "Day 5 and Day 26"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01967771"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Single 12-lead ECGs will be obtained at each timepoint", 
                "measure": "Change from baseline in 12-lead electrocardiogram (ECG)", 
                "safety_issue": "No", 
                "time_frame": "Up to 40 days"
            }, 
            {
                "description": "Vital signs will include systolic and diastolic blood pressure and pulse rate", 
                "measure": "Change from baseline in vital signs", 
                "safety_issue": "No", 
                "time_frame": "Up to 40 days"
            }, 
            {
                "description": "AEs will be assessed throughout the study", 
                "measure": "Number of subjects with adverse events (AEs)", 
                "safety_issue": "No", 
                "time_frame": "Up to 40 days"
            }, 
            {
                "description": "Laboratory assessments will include haematology, clinical chemistry and urinalysis parameters", 
                "measure": "Toxicity grading of clinical laboratory tests", 
                "safety_issue": "No", 
                "time_frame": "Up to 40 days"
            }
        ], 
        "source": "ViiV Healthcare", 
        "sponsors": {
            "collaborator": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "ViiV Healthcare", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}